The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 26, 2016

Filed:

Apr. 10, 2007
Applicants:

Hartmut Kupper, Mutterstadt, DE;

Jeffrey D. Kent, Deerfield, IL (US);

Mary A. Cifaldi, Gurnee, IL (US);

John L. Perez, Doylestown, PA (US);

Gerd R. Burmester, Berlin, DE;

Philip Mease, Seattle, WA (US);

Daniel J. Lovell, Cincinnati, OH (US);

Edward Keystone, Toronto, CA;

Arthur Kavanaugh, San Diego, CA (US);

Inventors:

Hartmut Kupper, Mutterstadt, DE;

Jeffrey D. Kent, Deerfield, IL (US);

Mary A. Cifaldi, Gurnee, IL (US);

John L. Perez, Doylestown, PA (US);

Gerd R. Burmester, Berlin, DE;

Philip Mease, Seattle, WA (US);

Daniel J. Lovell, Cincinnati, OH (US);

Edward Keystone, Toronto, CA;

Arthur Kavanaugh, San Diego, CA (US);

Assignee:

ABBVIE BIOTECHNOLOGY LTD, Hamilton, BM;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 39/39 (2006.01); C07K 16/24 (2006.01); A61K 39/09 (2006.01); A61K 39/145 (2006.01); C12N 7/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39 (2013.01); A61K 39/092 (2013.01); A61K 39/145 (2013.01); A61K 39/3955 (2013.01); C07K 16/241 (2013.01); C12N 7/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/55516 (2013.01); C07K 2316/96 (2013.01); C07K 2317/21 (2013.01); C07K 2317/30 (2013.01); C12N 2760/16034 (2013.01); C12N 2760/16071 (2013.01);
Abstract

The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of rheumatoid arthritis in a subject.


Find Patent Forward Citations

Loading…